China Biologic Products Special Committee Completes Investigation

China, Dec. 6, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) (“China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China (“PRC”), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. (“Shandong Taibang”) and Guiyang Dalin Biologic Technologies Co., Ltd. (“Dalin”), and its equity investment in Xi’an Huitian Blood Products Co., Ltd. (“Huitian”), today announced that the Special Committee of its Board of Directors has completed its investigation of several allegations that appeared on certain financial websites in January 2010. The Special Committee was comprised of the Company’s independent directors, Mr. Sean Shao, Dr. Tong Jun Lin, and later Dr. Xiangmin Cui, and advised by O’Melveny & Myers LLP, an international law firm. The summary key findings of the Special Committee were disclosed in a current report on Form 8-K filed by the Company with the Securities and Exchange Commission on December 4, 2010.

Independent director Mr. Sean Shao, who led the Special Committee of the Board of Directors, said, “I am very pleased that the Special Committee has completed its investigation and that the Company can now turn its full attention to developing, growing, and improving its business to the high potential that we believe it has.”

Mr. Chao Ming (Colin) Zhao, Chief Executive Officer of China Biologic, said, “I very much thank the Committee members for their work and their dedication to completing this important task for our company.”

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi’an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical companies in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company’s plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company’s website http://www.chinabiologic.com for additional information.

Safe Harbor Statement

This release may contain certain “forward-looking statements” relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are “forward-looking statements,” including statements regarding: the business strategy, plans, and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website http://www.sec.gov and on the Company’s website at http://www.chinabiologic.com. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

SOURCE China Biologic Products, Inc.